Insiders Trades
Revolution Medicines, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Dec 2024.
Revolution Medicines, Inc.: what insiders have been doing
Every trade that managers of Revolution Medicines, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 163 filings signed by 33 insiders.
No insider bought on the market over the period, while 11 insiders filed 96 sales totalling €77.7M. The totals do not cover 7 filings with an undisclosed amount. Goldsmith Mark A filed the largest sale, €15.3M, on 17 April 2026.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 163 filings here. The full history, which starts in 2021, counts 9 purchases against 212 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -1.13 bn USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
404
Thresholds
n/a
Buy Volume
€38M
9 ops. · all time
Sell Volume
€111M
212 ops. · all time
Who traded when
BuySaleGoldsmith Mark A28 sales
Jeff Cislini22 sales
Stephen Michael Kelsey16 sales
Anders Jack13 sales
Anthony Mancini13 sales
Margaret A. Horn8 sales
+6 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Revolution Medicines, Inc. Strong Buy (bullish), based on 24 analysts. Average price target: US$257.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$177.96
Analyst consensus
24 analystsStrong buy
US$179.00Target US$257.80(+45%)US$320.00
Income statement
EBITDA-US$1.1B
Net income-US$1.1B0.0% margin
Valuation
PER (forward)-30.5x
P/Book14.6x
Beta1.40
Balance sheet & cash
Market capUS$38.1B
Total debtUS$158.7M
Free Cash Flow-US$913.7M
Debt / Equity46%
Profitability & ownership
ROE-79.1%
ROA-30.1%
% insiders1.9%
% institutions102.3%
Last declaration on 1 October 2026
Declarations404 total
6,000 shares@ US$58.8420.8% of flowCommon StockSEC:0001835966-26-000008:0
2,200 shares@ US$200.818826.1% of flowCommon StockSEC:0001835966-26-000008:1
1,609 shares@ US$201.723919.1% of flowCommon StockSEC:0001835966-26-000008:2
1,000 shares@ US$202.812712.0% of flowCommon StockSEC:0001835966-26-000008:3
1,199 shares@ US$203.907414.4% of flowCommon StockSEC:0001835966-26-000008:4
301 shares@ US$204.72243.6% of flowCommon StockSEC:0001835966-26-000008:5
6,309 shares@ US$201.740.0029% mcap100.0% of flowCommonSEC144:0001950047-26-009862
765 shares@ US$207.32010.9% of flowCommon StockSEC:0001969082-26-000011:0
3,121 shares@ US$33.621.3% of flowCommon StockSEC:0002124509-26-000012:1
587 shares@ US$200.001.5% of flowCommon StockSEC:0002124509-26-000012:0
3,121 shares@ US$200.548.0% of flowCommon StockSEC:0002124509-26-000012:2
9,363 shares@ US$199.8680.4% of flowCommonSEC144:0001950047-26-009818
587 shares@ US$190.744.8% of flowCommonSEC144:0001950047-26-009803
5,070 shares@ US$1.120.3% of flowCommon StockSEC:0001758247-26-000004:0
910 shares@ US$191.85218.9% of flowCommon StockSEC:0001758247-26-000004:1
2,648 shares@ US$193.439226.1% of flowCommon StockSEC:0001758247-26-000004:3
1,500 shares@ US$194.588714.9% of flowCommon StockSEC:0001758247-26-000004:4
100 shares@ US$195.151.0% of flowCommon StockSEC:0001758247-26-000004:5
4,985 shares@ US$192.538748.9% of flowCommon StockSEC:0001758247-26-000004:2
15,080 shares@ US$192.760.0071% mcap100.0% of flowCommonSEC144:0001950047-26-009742
1,764 shares@ US$196.945.0% of flowCommon StockSEC:0002124509-26-000010:0
1,764 shares@ US$196.9414.8% of flowCommonSEC144:0001950047-26-009664
4,891 shares@ US$199.303211.3% of flowCommon StockSEC:0001294192-26-000007:1
85 shares@ US$195.00740.1% of flowCommon StockSEC:0001462808-26-000010:0
5 shares@ US$194.95891.4% of flowCommon StockSEC:0001835966-26-000006:0
25 of 404 declarations
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ market, and it is based in Redwood City, California, in the United States. For international investors, the company represents a focused precision-oncology story rather than a broad commercial pharmaceutical platform. Its core strategy is to develop therapies for so-called RAS-addicted cancers, tumors whose growth is driven by oncogenic RAS pathway mutations. That scientific focus places Revolution Medicines in a specialized, research-intensive segment of biotech, where valuation is largely determined by clinical execution and data quality.
The company was founded in 2014 and has spent the intervening years building a pipeline around the long-standing challenge of inhibiting RAS biology. Its programs center on RAS(ON) inhibitors designed to target active RAS proteins and specific oncogenic variants. The lead candidate is daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor. Other major assets include elironrasib (RMC-6291), a G12C-selective inhibitor; zoldonrasib (RMC-9805), a G12D-selective inhibitor; and RMC-5127, a G12V-selective inhibitor. The company is also pursuing additional opportunities in other RAS mutation settings, including Q61H and G13C.
Read moreShow less
From a competitive perspective, Revolution Medicines stands out because it is trying to address multiple mutation hotspots within one of oncology’s most commercially and medically important pathways. Its opportunity set is concentrated in high-unmet-need cancers such as pancreatic cancer and certain lung cancer populations. As a result, the investment case is highly catalyst-driven: the company’s trajectory depends on clinical readouts, durability of response, safety/tolerability, regulatory engagement, and ultimately the ability to turn early signals into approvable, differentiated therapies.
Recent developments have reinforced that profile. In April 2026, Revolution Medicines reported updated Phase 1/2 data for daraxonrasib in first-line metastatic pancreatic cancer and also highlighted positive pivotal Phase 3 RASolute 302 results in previously treated metastatic pancreatic cancer. The company also completed a large capital raise in April 2026 through an upsized common-stock and convertible-note offering, underscoring the funding intensity typical of late-stage oncology development. In May 2026, it reported first-quarter 2026 financial results and continued to emphasize progress across its RAS(ON) pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
